Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zynerba Pharma CS (ZYNE)

Zynerba Pharma CS (ZYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 70,121
  • Shares Outstanding, K 53,939
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,040 K
  • EBIT $ -39 M
  • EBITDA $ -39 M
  • 60-Month Beta 1.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.40
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.80
  • Most Recent Earnings $-0.21 on 08/14/23
  • Next Earnings Date 11/13/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.20
  • Number of Estimates 2
  • High Estimate -0.19
  • Low Estimate -0.20
  • Prior Year -0.20
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1850 +9.70%
on 10/04/23
1.4000 -7.14%
on 09/15/23
-0.0200 (-1.52%)
since 09/08/23
3-Month
0.2500 +420.00%
on 07/11/23
1.4000 -7.14%
on 09/15/23
+0.9698 (+293.70%)
since 07/10/23
52-Week
0.2500 +420.00%
on 07/11/23
1.4000 -7.14%
on 09/15/23
+0.6002 (+85.77%)
since 10/10/22

Most Recent Stories

More News
Why Shares of Harmony Bioscience Are Falling on Friday

The company reported underwhelming phase 3 trial results for Pitolisant to treat idiopathic hypersomnia.

ZYNE : 1.3000 (+2.36%)
HRMY : 34.07 (+2.53%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPRI, CEQP, CELL, ZYNE

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CPRI : 20.48 (+3.96%)
CEQP : 28.26 (+4.36%)
CELL : 0.9981 (+0.31%)
ZYNE : 1.3000 (+2.36%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVID, ZYNE, HEP, CEQP

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AVID : 27.04 (unch)
ZYNE : 1.3000 (+2.36%)
HEP : 20.45 (-0.78%)
CEQP : 28.26 (+4.36%)
Shareholder Alert: Ademi LLP investigates whether Zynerba Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Harmony

/PRNewswire/ -- Ademi LLP is investigating Zynerba (Nasdaq: ZYNE) for possible breaches of fiduciary duty and other violations of law in its transaction with...

ZYNE : 1.3000 (+2.36%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CPRI, AVID, ZYNE, HEP

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

CPRI : 20.48 (+3.96%)
AVID : 27.04 (unch)
ZYNE : 1.3000 (+2.36%)
HEP : 20.45 (-0.78%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TRHC, DBTX, VRTV, ZYNE

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TRHC : 10.50 (+0.86%)
DBTX : 4.91 (-0.81%)
VRTV : 169.99 (+0.02%)
ZYNE : 1.3000 (+2.36%)
Zynerba: Q2 Earnings Snapshot

Zynerba: Q2 Earnings Snapshot

ZYNE : 1.3000 (+2.36%)
HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative...

HRMY : 34.07 (+2.53%)
ZYNE : 1.3000 (+2.36%)
Zynerba: Q1 Earnings Snapshot

Zynerba: Q1 Earnings Snapshot

ZYNE : 1.3000 (+2.36%)
Zynerba: Q4 Earnings Snapshot

Zynerba: Q4 Earnings Snapshot

ZYNE : 1.3000 (+2.36%)

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

3rd Resistance Point 1.4200
2nd Resistance Point 1.3800
1st Resistance Point 1.3400
Last Price 1.3000
1st Support Level 1.2600
2nd Support Level 1.2200
3rd Support Level 1.1800

See More

52-Week High 1.4000
Last Price 1.3000
Fibonacci 61.8% 0.9607
Fibonacci 50% 0.8250
Fibonacci 38.2% 0.6893
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar